US Court Refuses To Rehear Hatch-Waxman Venue Case
Valeant Petition For Full ‘En Banc’ Rehearing Fails
A ruling that could play a key role in limiting venue for Hatch-Waxman litigation in the US will not be reviewed by the full US Court of Appeals for the Federal Circuit after it refused a rehearing petition by Valeant.
You may also be interested in...
An appeals court ruling in the US stands to “drastically change” the venue options for brand companies to sue ANDA filers.
Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.
Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.